Gilead’s ADC Medicine Falls Short of Target in Highly Monitored Lung Cancer Study Gilead Sciences, a leading biopharmaceutical company, recently...
Title: Promising Results: First Patient in Phase 1 Clinical Trial of PMB-CT01 Achieves Complete Remission for Relapsed and Refractory B-cell...
Recap of the Fnatic vs Team Vitality Match in the LEC 2024 Winter Season Week 1 The League of Legends...
Introducing LoL Smolder’s New ADC: A Comprehensive Guide League of Legends (LoL) is a highly popular online multiplayer game that...
LegoChem Biosciences, a leading biopharmaceutical company based in South Korea, has recently announced a licensing deal with Janssen Pharmaceuticals, a...
Sanofi, one of the world’s leading pharmaceutical companies, recently announced the discontinuation of the development of tusamitamab ravtansine, a potential...
GSK Expands ADC Dealings by Establishing Second Biotech Partnership in China GlaxoSmithKline (GSK), a leading global pharmaceutical company, has recently...
Pfizer, one of the world’s leading pharmaceutical companies, has recently announced a collaboration with Nona, a biotechnology company specializing in...
Bristol Myers Squibb, a leading global biopharmaceutical company, recently announced its acquisition of SystImmune for a whopping $800 million. This...
AbbVie, a global biopharmaceutical company, has recently announced its acquisition of Immunogen, a leading manufacturer of targeted cancer medications, in...
Understanding the ADC Buying Spree: An Analysis of Mergers and Acquisitions In recent years, the Application Delivery Controller (ADC) market...
ESMO 2023: A Comprehensive Overview of ADCs in Catalyst Clinical Research The European Society for Medical Oncology (ESMO) is one...
Fertility preservation is a crucial concern for individuals facing medical treatments that may compromise their reproductive capabilities. In recent years,...
Seagen and Nurix Collaborate to Develop Innovative Cancer Medication Seattle Genetics (Seagen) and Nurix Therapeutics have recently announced a collaboration...
A New Therapeutic Agent for T Cell Lymphoma – Leukemia: The Potential of CD6-Targeted Antibody-Drug Conjugate T cell lymphoma-leukemia is...
